Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lorenzo Gerratana

Showing results (91-100 of 127) with videos related to

Pageof 13
Sort By:
Viruses|June 28, 2023
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile SubjectsGiulia Brisotto, Marcella Montico, Matteo Turetta, et al.
Translational Oncology|June 27, 2025
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomicsLorenzo Foffano, Alessandra Franzoni, Elisabetta Molteni, et al.
Therapeutic Advances in Medical Oncology|March 20, 2023
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapyGiovanna Garufi, Luisa Carbognin, Isabella Sperduti, et al.
Journal of Geriatric Oncology|December 16, 2018
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world studyValentina Fanotto, Lorenzo Fornaro, Roberto Bordonaro, et al.
NPJ Breast Cancer|June 29, 2021
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancerFabio Puglisi, Lorenzo Gerratana, Matteo Lambertini, et al.
Cancer Letters|November 22, 2024
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profilingLorenzo Gerratana, Andrew A Davis, Lorenzo Foffano, et al.
The Journal of Pathology|October 25, 2024
A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitorsIlenia Segatto, Maria Chiara Mattevi, Gian Luca Rampioni Vinciguerra, et al.
NPJ Breast Cancer|June 8, 2023
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancerLuca Licata, Giulia Viale, Mario Giuliano, et al.
Science Translational Medicine|March 11, 2026
Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic valueCarolina Reduzzi, Eleonora Nicolò, Lorenzo Gerratana, et al.
JCO Precision Oncology|May 4, 2023
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker AnalysisLorenzo Gerratana, Andrew A Davis, Marko Velimirovic, et al.
Pageof 13

Showing results (91-100 of 127) with videos related to

Sort By:
Pageof 13
Viruses|June 28, 2023
Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile SubjectsGiulia Brisotto, Marcella Montico, Matteo Turetta, et al.
Translational Oncology|June 27, 2025
Longitudinal profiling of hormone receptor positive, HER2 negative metastatic breast cancer through droplet digital PCR-based circulating tumor DNA fragmentomicsLorenzo Foffano, Alessandra Franzoni, Elisabetta Molteni, et al.
Therapeutic Advances in Medical Oncology|March 20, 2023
Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapyGiovanna Garufi, Luisa Carbognin, Isabella Sperduti, et al.
Journal of Geriatric Oncology|December 16, 2018
Second-line treatment efficacy and toxicity in older vs. non-older patients with advanced gastric cancer: A multicentre real-world studyValentina Fanotto, Lorenzo Fornaro, Roberto Bordonaro, et al.
NPJ Breast Cancer|June 29, 2021
Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancerFabio Puglisi, Lorenzo Gerratana, Matteo Lambertini, et al.
Cancer Letters|November 22, 2024
Integrating machine learning-predicted circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in metastatic breast cancer: A proof of principle study on endocrine resistance profilingLorenzo Gerratana, Andrew A Davis, Lorenzo Foffano, et al.
The Journal of Pathology|October 25, 2024
A comprehensive luminal breast cancer patient-derived xenografts (PDX) library to capture tumor heterogeneity and explore the mechanisms of resistance to CDK4/6 inhibitorsIlenia Segatto, Maria Chiara Mattevi, Gian Luca Rampioni Vinciguerra, et al.
NPJ Breast Cancer|June 8, 2023
Oncotype DX results increase concordance in adjuvant chemotherapy recommendations for early-stage breast cancerLuca Licata, Giulia Viale, Mario Giuliano, et al.
Science Translational Medicine|March 11, 2026
Dual-positive CTCs in patients with advanced breast cancer show metastatic potential and prognostic valueCarolina Reduzzi, Eleonora Nicolò, Lorenzo Gerratana, et al.
JCO Precision Oncology|May 4, 2023
Cyclin-Dependent Kinase 4/6 Inhibitors Beyond Progression in Metastatic Breast Cancer: A Retrospective Real-World Biomarker AnalysisLorenzo Gerratana, Andrew A Davis, Marko Velimirovic, et al.
Pageof 13